Create Account
Sign In
Dark
chart
exchange
Terminal
Screener
Stocks
Crypto
Forex
Watchlists
Trends

PYPD
Polypid Ltd
stock NASDAQ

At Close
3/24/2023 3:59:30 PM EDT
0.4700USD+9.302%(+0.0400)49,857
0.3600Bid   0.5760Ask   0.2160Spread IEX
Pre-market
3/22/2023 8:51:30 AM EDT
0.5100USD+18.605%(+0.0800)0
After-hours
1969-12-31
0.00USD0.000%(0.00)0
OverviewOption ChainHistoricalExchange VolumeShort VolumeBorrow FeeFailure to DeliverTrendsNewsNews
Jan 26, 2022
07:30AM EST  PolyPid to Report Fourth Quarter and Full Year 2021 Financial   GlobeNewswire Inc
Jan 4, 2022
07:30AM EST  PolyPid Appoints UCSF Brain Tumor Center Director Mitchel S.   GlobeNewswire Inc
Jan 3, 2022
08:17AM EST  PolyPid Ltd. (PYPD), an Israeli biopharmaceutical firm, said on Monday that its Chief Executive Officer or CEO Amir Weisberg, will retire from the service with effect from July 1.   RTTNews
07:37AM EST  PolyPid Appoints Dikla Czaczkes Akselbrad As CEO, Effective July 1   RTTNews
07:31AM EST  PolyPid Appoints Dikla Czaczkes Akselbrad CEO   Benzinga
07:30AM EST  PolyPid Announces Planned CEO Transition   GlobeNewswire Inc
Nov 18, 2021
07:05AM EST  PolyPid Announces 500th Patient Enrolled In SHIELD I Phase 3 Clinical Trial Of D-PLEX In Abdominal Surgery   Benzinga
07:00AM EST  PolyPid Announces 500th Patient Enrolled in SHIELD I Phase 3   GlobeNewswire Inc
Nov 16, 2021
07:00AM EST  PolyPid Ltd. (Nasdaq: PYPD) (PolyPid or the Company), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced the appointment of Frederick Lang, M.D., to its Oncology Advisory Board.   GlobeNewswire Inc
Nov 10, 2021
07:32AM EST  PolyPid Q3 EPS $(0.53) Beats $(0.62) Estimate   Benzinga
07:00AM EST  Recruitment Progressing as Planned with Approximately 480 Patients Enrolled in Phase 3 SHIELD I Trial of D-PLEX100in Abdominal Surgery   GlobeNewswire Inc
04:09AM EST  Earnings Scheduled For November 10, 2021   Benzinga
Nov 1, 2021
07:00AM EDT  PolyPid to Report Third Quarter 2021 Financial Results and   GlobeNewswire Inc
Oct 18, 2021
10:21AM EDT  Overview Of Value Stocks In The Healthcare Sector   Benzinga
Sep 20, 2021
10:44AM EDT  5 Value Stocks In The Healthcare Sector   Benzinga
07:00AM EDT  PolyPid Ltd. (Nasdaq: PYPD), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29 at 02:00 pm EDT.   GlobeNewswire Inc
Sep 14, 2021
10:16AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2021   Benzinga
06:23AM EDT  JMP Securities Initiates Coverage On PolyPid with Market Outperform Rating, Announces Price Target of $14   Benzinga
Sep 13, 2021
10:27AM EDT  A Look Into Healthcare Sector Value Stocks   Benzinga
07:49AM EDT  PolyPid Announces Positive Preclinical Data Of Its Intra-tumoral OncoPLEX In Brain Cancer   RTTNews
07:42AM EDT  PolyPid Announces Preclinical Data In Glioblastoma Multiform Animal Models Of OncoPLEX Program; Says Results Demonstrated 'Single Local Treatment of OncoPLEX Significantly Inhibited Tumor Growth and Prolonged Survival'   Benzinga
07:30AM EDT  -- Positive Results in Two Animal Models of Glioblastoma Multiform (GBM) demonstrated that Single Local Treatment of OncoPLEX Significantly Inhibited Tumor Growth and Prolonged Survival -- Company Expects a Pre-IND Meeting with the U.S. FDA by Year End and Potential Initiation of Phase 1/2 Clinical Trial of OncoPLEX in Brain Tumors in 2022   GlobeNewswire Inc
Aug 17, 2021
08:00AM EDT  PolyPid to Present at First World Association Against Infection in   GlobeNewswire Inc
Aug 11, 2021
09:06AM EDT  Earnings Scheduled For August 11, 2021   Benzinga
07:29AM EDT  PolyPid Q2 EPS $(0.56) Misses $(0.52) Estimate   Benzinga
07:00AM EDT  Recruitment Progressing as Planned with Over300 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100in Abdominal Surgery   GlobeNewswire Inc
04:27AM EDT  Earnings Scheduled For August 11, 2021   Benzinga
Aug 9, 2021
08:00AM EDT  PolyPid Ltd.(Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that Executive Vice President and Chief Financial Officer Dikla Czaczkes Akselbrad will present a corporate overview at the Investor Summit Virtual Conference being held August 17 18, 2021.   GlobeNewswire Inc
Jul 30, 2021
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 30, 2021   Benzinga
07:49AM EDT  Cantor Fitzgerald Initiates Coverage On PolyPid with Overweight Rating, Announces Price Target of $24   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
07:00AM EDT  PolyPid to Report Second Quarter 2021 Financial Results and   GlobeNewswire Inc
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 14, 2021
07:48AM EDT  The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues   Benzinga
Jul 12, 2021
08:00AM EDT  PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company focusing on developing targeted, locally administered and prolonged-release therapeutics to improve surgical outcomes, today announced that it has appointed leading colorectal surgeon Anthony J. Senagore, M.D., as its Senior Medical Director.   GlobeNewswire Inc
Jul 2, 2021
04:28PM EDT  PolyPid Files For Stock Shelf Offering Of Up To $200M   Benzinga
Jun 23, 2021
06:30AM EDT  PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, announced that Dikla Czaczkes Akselbrad, Executive Vice President and Chief Financial Officer will present today at The Raymond James Human Health Innovation Conference at 9:20 am EDT.   GlobeNewswire Inc
Jun 2, 2021
09:10AM EDT  PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that members of its executive management team will present at three upcoming healthcare investor conferences.   GlobeNewswire Inc
May 19, 2021
12:53PM EDT  PolyPid's Single Pivotal Study Sufficient To Support Potential Approval Of D-PLEX100 For Infections After Colorectal Surgery   Benzinga
08:03AM EDT  PolyPid Reports Positive FDA Type B Meeting Feedback For D-PLEX100 Development Program   Benzinga
08:00AM EDT  FDA Agreed that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX100for the Prevention of Surgical Site Infections in Colorectal Surgery.   GlobeNewswire Inc
May 13, 2021
08:10AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
07:13AM EDT  PolyPid Q1 EPS $(0.47) Beats $(0.50) Estimate   Benzinga
07:00AM EDT  Recruitment Progressing as Planned with Nearly 200 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery   GlobeNewswire Inc
04:22AM EDT  Earnings Scheduled For May 12, 2021   Benzinga
Apr 29, 2021
07:00AM EDT  PolyPid to Report First Quarter 2021 Financial Results and   GlobeNewswire Inc
Mar 31, 2021
07:41AM EDT  The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO   Benzinga
Feb 23, 2021
07:30AM EST  PolyPid to Participate in Upcoming Investor Conferences   GlobeNewswire Inc
Feb 16, 2021
07:35AM EST  PolyPid Highlights 100th Patient Enrolled In SHIELD I Phase 3 Clinical Trial Of D-PLEX For The Prevention Of Post-Abdominal Surgery Incisional Infections   Benzinga
07:31AM EST  PolyPid Announces 100th Patient Enrolled in SHIELD I Phase 3   GlobeNewswire Inc
Feb 11, 2021
11:21AM EST  Stocks That Hit 52-Week Highs On Thursday   Benzinga
Feb 10, 2021
07:34AM EST  The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs   Benzinga
07:07AM EST  PolyPid Q4 EPS $(0.41) Beats $(0.51) Estimate   Benzinga
07:00AM EST  -- 100Patients Enrolled into Phase 3 SHIELD I and SHIELD II Trialsof D-PLEX100 in Abdominal Surgery -- Recently Initiated Phase 3 SHIELD II Trial -- Granted Breakthrough Therapy Designation from FDA for D-PLEX100 for Prevention of SSIs in Patients Undergoing Elective Colorectal Surgery -- Conference Call Scheduled for Today at 8:30AMET   GlobeNewswire Inc
03:43AM EST  Earnings Scheduled For February 10, 2021   Benzinga
Feb 6, 2021
12:42PM EST  The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight   Benzinga
Jan 27, 2021
07:30AM EST  PolyPid to Report Fourth Quarter and Full Year 2020 Financial   GlobeNewswire Inc
Dec 22, 2020
07:09AM EST  PolyPid Reports Preclinical Data From OncoPLEX Intra-Tumoral Cancer Therapy Program: Showed Overall Survival, Significantly Less Tumor Recurrence   Benzinga
07:04AM EST  PolyPid Announces Positive Preclinical Data From OncoPLEX Intra-Tumoral Cancer Therapy Program   RTTNews
07:00AM EST  Single Local Treatment of OncoPLEX Showed Improved Overall Survival and Significantly Less Tumor Recurrence, and Reduced Systemic Toxicity Compared to Multiple Injections with Standard Systemic Chemotherapy in a Syngeneic Mouse Model for Solid Tumors of Colon Carcinoma   GlobeNewswire Inc
03:57AM EST  The lockup period of PolyPid Ltd. (PYPD) ends tomorrow, i.e., December 23.   RTTNews
Dec 16, 2020
07:11AM EST  PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial Of D-PLEX For Prevention Of Post-Abdominal Surgery Incisional Infections   Benzinga
07:01AM EST  Enrollment in SHIELD I, the First Phase 3 Clinical Trial Continues to Progress, with Top-line Data Anticipated in Second Half of 2021   GlobeNewswire Inc
Dec 3, 2020
08:00AM EST  PolyPid to Host Key Opinion Leader Call Discussing   GlobeNewswire Inc
Nov 24, 2020
08:18AM EST  PolyPid Reports Was Granted Breakthrough Therapy Designation From FDA For D-PLEX For Prevention Of Surgical Site Infections In Colorectal Surgery   Benzinga
08:17AM EST  PolyPid Granted Breakthrough Therapy Designation from FDA for   GlobeNewswire Inc
Nov 20, 2020
08:06AM EST  The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger   Benzinga
Nov 19, 2020
08:17AM EST  The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway   Benzinga
Nov 12, 2020
07:44AM EST  The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal   Benzinga
Nov 11, 2020
07:38AM EST  The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap   Benzinga
06:34AM EST  PolyPid Q3 EPS $(0.35) Beats $(0.39) Estimate   Benzinga
06:30AM EST  Over 50% of planned 60 centers for ongoing Phase 3 SHIELD I trial of D-PLEX100in abdominal surgeryhave received IRB approval   GlobeNewswire Inc
04:09AM EST  Earnings Scheduled For November 11, 2020   Benzinga
Nov 4, 2020
08:45AM EST  PolyPid to Participate in Three Upcoming Investor Conferences   GlobeNewswire Inc
Oct 28, 2020
07:00AM EDT  PolyPid to Report Third Quarter 2020 Financial Results and   GlobeNewswire Inc
Aug 19, 2020
07:21AM EDT  PolyPid Q2 EPS $(6.37) Misses $(0.37) Estimate   Benzinga
07:00AM EDT  Initiated Phase 3 SHIELD I Trial for D-PLEX100 in Abdominal Surgery and Received Fast Track Designation for D-PLEX100from FDA   GlobeNewswire Inc
04:02AM EDT  Earnings Scheduled For August 19, 2020   Benzinga
Aug 10, 2020
10:25AM EDT  Benzinga's Top Upgrades, Downgrades For August 10, 2020   Benzinga
07:14AM EDT  Alliance Global Partners Initiates Coverage On PolyPid with Buy Rating, Announces Price Target of $27   Benzinga
Aug 5, 2020
04:02PM EDT  PolyPid to Report Second Quarter 2020 Financial Results and   GlobeNewswire Inc
Aug 3, 2020
07:20AM EDT  PolyPid Gets FDA Fast Track Designation For D-PLEX For Prevention Of Surgical Site Infections In Abdominal Surgery   RTTNews
07:05AM EDT  PolyPid Granted Fast Track Designation from FDA for D-PLEX for Prevention of Surgical Site Infections in Abdominal Surgery   Benzinga
07:00AM EDT  PolyPid Granted Fast Track Designation from FDA for   GlobeNewswire Inc
Jul 27, 2020
07:00AM EDT  PolyPid to Present Phase 2 Results of   GlobeNewswire Inc
Jul 21, 2020
09:37AM EDT  Benzinga's Top Upgrades, Downgrades For July 21, 2020   Benzinga
08:19AM EDT  Raymond James Initiates Coverage On PolyPid with Outperform Rating, Announces Price Target of $23   Benzinga
07:27AM EDT  BMO Capital Initiates Coverage On PolyPid with Outperform Rating, Announces Price Target of $30   Benzinga
06:06AM EDT  Barclays Initiates Coverage On PolyPid with Overweight Rating, Announces Price Target of $22   Benzinga


Share
About
Symbol List

Pricing
Disclaimer

ChartExchange on Twitter
ChartExchange on Reddit
© 2020 - 2023 ChartExchange LLC